Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.41 |
| ▸ | AHR | P35869 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987451 | 0.88 | AMY1A (0.43) | ADORA3TP53ADORA1ADORA2APDE10A | |
| SCHEMBL22987491 | 0.87 | ADORA3 (0.52) | ADORA3TP53ADORA1ADORA2ANPC1 | |
| SCHEMBL22987455 | 0.84 | ADORA3 (0.46) | ADORA3TP53ADORA1ADORA2ANPC1 | |
| SCHEMBL22987473 | 0.83 | NR1H2 (0.42) | ADORA3TP53ADORA1ADORA2APDE10A | |
| SCHEMBL22987587 | 0.82 | ADORA3 (0.39) | ADORA3TP53ADORA1ADORA2APDE10A | |
| SCHEMBL22987977 | 0.80 | TP53 (0.47) | ADORA3AHRTP53ADORA1ADORA2A | |
| SCHEMBL22979754 | 0.79 | ADORA3 (0.61) | ADORA3TP53ADORA1ADORA2ARXFP1 | |
| SCHEMBL29646319 | 0.79 | ADORA3 (0.61) | ADORA3TP53ADORA1ADORA2ARXFP1 | |
| SCHEMBL22987454 | 0.79 | ADORA3 (0.38) | ADORA3ADORA1ADORA2APDE10ARXFP1 | |
| SCHEMBL29450035 | 0.76 | TOP1 (0.43) | ADORA3TP53ADORA1ADORA2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885AHR 1/4885TP53 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.